More Videos
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- GM, Ford & Chrysler CEOs Take Their Medicine
- Daschle's Dollars From Lawyers, Not Pharma
- Another "Short" Story About Pfizer & Dendreon
- Stock Picker: Ride the Bat Out Of Hell
- Like A Business, Review Your Own Resources
- Are Toys Too Pricey for a Recession?
- Busch: Success Also Means Reform Of System
- Highest Dividend Yields of the Dow
- Newspaper Ad Revenues Take Even Bigger Fall
- D-Day For Big 3: Will They "Land" Congress With New Plans?
- Access To Credit: Why Younger Generation Needs It
- Putting a Value on a C.E.O.
- Where the Layoffs Are—Is Your Firm on the List?
- Treasurys Lower With Little Room to Grow
- BofA to Cut 10,000 Investment Banking Jobs
- GE to Maintain Dividend, Streamline Finance Arm
- Delta Air to Reduce Capacity By 6 to 8 Percent
- British Airways Discusses Merger with Qantas
- Cash—Not Gold—Is New Safe Haven for Investors
- Beazer Homes Loss Balloons as Revenue Plunges
Text Size 
 |
The Wall Street Journal unmasked the identity--Eli Lilly--of ImClone's secret suitor. A spokesman for LLY said he couldn't confirm or deny the report.
IMCL put out a press release last night saying that the mystery bidder has asked to remain anonymous.
And, interestingly, the press release no longer put a dollar amount on the "proposal" that's supposedly on the table.
That could explain why shares of IMCL are trading well below the $70 that ImClone originally claimed was the competing bidder's offer. Shares of IMCL[IMCL
Loading...
()
], which spiked on the news late yesterday about LLY's [LLY
Loading...
()
] interest, have been trading up and down today.
Miller Tabak healthcare analyst Les Funtleyder is enjoying this Carl Icahn-driven story as much as I am. In a research note to clients this morning he writes, "The kabuki theateresque news flow that this transaction has encouraged will likely continue." Icahn is a big investor in and the Chairman of ImClone. At least he's keeping things interesting for folks whose attention to the bailout story might be waning. His last statement called BMY's[BMY
Loading...
()
] $62-a-share offer "absurd."
Meantime, Mike King at Rodman & Renshaw is telling clients to stay on the sidelines because, "We do not envision a materially higher counter offer from Bristol." A spokesman for BMY said, "No comment," regarding the WSJ report about LLY. R&R makes a market in IMCL.
LLY bought its impotence drug partner Icos. It consistently denies that it's interested in buying its diabetes drug partner Amylin Pharmaceuticals[AMLYN
Loading...
()
] . But several analysts and industry-watchers think buying IMCL makes sense for LLY which, like a lot of other big drug companies, may want to increase its footprint in oncology.
No matter who gets ImClone, if anyone, what is it about this limelight-loving biotech? First, it was made infamous by a trading scandal that ensnared one of the most famous women in America. Then, one of the most colorful activist investors in the world takes a stake in it, helps revive the stock, and now is apparently orchestrating a juicy, little bidding war. As Deutsche Bank's Barbara Ryan writes in a research note to clients today, "It remains interesting. Rather than predict (the outcome), we will watch this scenario play out."
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes